OBJECTIVES: development of cytomegalovirus (CMV)-specific CD8+ T cell response is crucial in preventing symptomatic CMV infection specially, in stem cell transplant (SCT) patients. The aim of this study was to evaluate CMV-specific CD8+ T cell reconstitution in allogeneic SCT recipients and to study the possible association between CMV-specific CD8+ T cell recovery with protection from CMV reactivation and persistency. METHODS: Human leuKocyte antigen (HLA)-tetramers were used for CMV-specific CD8+ cell quantitation by Flow cytometry in twenty post-allogeneic SCT patients. RESULTS: Nine patients (45%) developed rapid recovery of CMV-specific CD8+ cells, among them; 7 patients (78%) had no CMV reactivation in the first 95 days post-transplant. Five patients had developed persistent CMV viremia; all of them had not developed CMV-specific CD8+ recovery till day 95 post-transplant. Patients with persistent CMV viremia had a statistically significant lower means of CMV-specific CD8+ percent and absolute count compared to those without persistent viremia (p = .001, .015), respectively. DISCUSSION: The incidence of CMV reactivation and persistency was higher among patients with delayed CMV-specific CD8+ reconstitution in the first 95 days post-transplant. CONCLUSION: CMV-specific CD8+ cells can help in categorizing patients into risk groups: (early recovery/low risk) and (delayed recovery/increased risk), this tool may guide clinicians in the selection of patients who may profit from prophylactic antiviral therapy and frequent viral monitoring.
OBJECTIVES: development of cytomegalovirus (CMV)-specific CD8+ T cell response is crucial in preventing symptomatic CMV infection specially, in stem cell transplant (SCT) patients. The aim of this study was to evaluate CMV-specific CD8+ T cell reconstitution in allogeneic SCT recipients and to study the possible association between CMV-specific CD8+ T cell recovery with protection from CMV reactivation and persistency. METHODS:Human leuKocyte antigen (HLA)-tetramers were used for CMV-specific CD8+ cell quantitation by Flow cytometry in twenty post-allogeneic SCT patients. RESULTS: Nine patients (45%) developed rapid recovery of CMV-specific CD8+ cells, among them; 7 patients (78%) had no CMV reactivation in the first 95 days post-transplant. Five patients had developed persistent CMV viremia; all of them had not developed CMV-specific CD8+ recovery till day 95 post-transplant. Patients with persistent CMV viremia had a statistically significant lower means of CMV-specific CD8+ percent and absolute count compared to those without persistent viremia (p = .001, .015), respectively. DISCUSSION: The incidence of CMV reactivation and persistency was higher among patients with delayed CMV-specific CD8+ reconstitution in the first 95 days post-transplant. CONCLUSION: CMV-specific CD8+ cells can help in categorizing patients into risk groups: (early recovery/low risk) and (delayed recovery/increased risk), this tool may guide clinicians in the selection of patients who may profit from prophylactic antiviral therapy and frequent viral monitoring.
Authors: Eva Wagner-Drouet; Daniel Teschner; Christine Wolschke; Dietlinde Janson; Kerstin Schäfer-Eckart; Johannes Gärtner; Stephan Mielke; Martin Schreder; Guido Kobbe; Mustafa Kondakci; Inken Hilgendorf; Marie von Lilienfeld-Toal; Stefan Klein; Daniela Heidenreich; Sebastian Kreil; Mareike Verbeek; Sandra Grass; Markus Ditschkowski; Tanja Gromke; Martina Koch; Monika Lindemann; Thomas Hünig; Traudel Schmidt; Anne Rascle; Harald Guldan; Sascha Barabas; Ludwig Deml; Ralf Wagner; Daniel Wolff Journal: Haematologica Date: 2021-02-01 Impact factor: 9.941
Authors: Harry Pickering; Subha Sen; Janice Arakawa-Hoyt; Kenichi Ishiyama; Yumeng Sun; Rajesh Parmar; Richard S Ahn; Gemalene Sunga; Megan Llamas; Alexander Hoffmann; Mario Deng; Suphamai Bunnapradist; Joanna M Schaenman; David W Gjertson; Maura Rossetti; Lewis L Lanier; Elaine F Reed Journal: JCI Insight Date: 2021-11-08